iMig Special Keynote Lecture: “Cancer Stem Cells as Target Pathways”
Presenter: Robert Weinberg, Ph.D., Whitehead Institute and Verastem scientific cofounder and chair of the Scientific Advisory Board

Presentation Title: “Determination of Biomarker response in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Subjects with Resectable MPM”
Presenter: Raphael Bueno, M.D., Chief, Division of Thoracic Surgery, Brigham & Women’s Hospital, Boston, MA

Presentation Title: “FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy”
Presenter: Paul Baas, M.D., Ph. D., Department of Thoracic Oncology,The Netherlands Cancer Institute

Presentation Title: “The Cancer Stem Cell Inhibitors VS-6063 (Defactinib) and VS-5584 Exhibit Synergistic Anticancer Activity in Preclinical Models of Mesothelioma”
Presenter: Mitchell Keegan, Ph.D., Vice President, Development, Verastem